Every material Form 8-K Bluejay Diagnostics, Inc. has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bluejay Diagnostics (Nasdaq: BJDX) completed a 1-for-4 reverse stock split effective November 3, 2026. The Board selected the ratio from a range of 1-for-2 to 1-for-20 that stockholders approved in June, and the cut reduced common shares outstanding from about 4,468,051 to about 1,117,013. The par value and voting rights are unchanged, and holders of fractional shares will receive cash, but the press release describes a three-for-one combination while the 8-K describes four-for-one, so the terms should be confirmed with the transfer agent.
Split effective 12:01 a.m. Eastern Time on November 3, 2026; BJDX began trading post-split on the Nasdaq Capital Market under new CUSIP 095633707.
Common shares outstanding fell from about 4,468,051 to about 1,117,013; prefunded warrant shares fell from 222,581 to 55,646 (press release says 55,645).
Stockholders approved the split at the June 9, 2026 annual meeting; the Board chose 1-for-4 and the certificate was filed October 30, 2026.
Fractional-share holders receive cash based on the recent average closing price; the press release describes every three shares combining into one, conflicting with the 8-K's four-for-one terms.
Bluejay Diagnostics said on October 13, 2026 that it has completed establishing a manufacturing site for Symphony cartridges, ahead of an October 23, 2026 contractual deadline under its amended license agreement with Toray Industries. The filing states the milestone is a step toward regulatory submission and potential commercialization, but it reports no revenue, earnings or guidance figures.
Milestone completed ahead of the October 23, 2026 deadline in the amended Toray Industries license agreement.
Manufacturing site is SanyoSeiko Co., Ltd. in Japan; ALURIS Sciences in the United States is a complementary manufacturing partner.
The Symphony IL-6 Test has not been cleared or approved by the FDA and is not available for commercial clinical use in the United States.
The filing contains no financial results, guidance or dollar figures.
Bluejay Diagnostics released baseline clinical characteristics from its SYMON-II clinical validation study of IL-6 as a biomarker for 28-day mortality risk in sepsis and septic shock. The company says the data do not by themselves establish the test's prognostic performance, and the Symphony IL-6 Test has not been cleared by the FDA and is not available for commercial clinical use in the United States.
Preliminary analysis includes 777 evaluable patients: 637 28-day survivors and 140 28-day non-survivors, an overall mortality rate of approximately 18%.
Septic shock was present in 56.4% of non-survivors compared with 35.8% of survivors.
The company plans to use SYMON-II, the pivotal study, to support a 510(k) application to the FDA.
The Symphony IL-6 Test has not been cleared or approved by the FDA.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bluejay Diagnostics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →